BDC-3042, a novel Dectin-2 agonistic antibody that stimulates the innate immune system, is being evaluated in a Phase 1/2 dose-escalation and expansion study in patients with a broad range of solid.
REDWOOD CITY, Calif., Oct. 16, 2023 Bolt Biotherapeutics, Inc. , a clinical-stage biopharmaceutical company pioneering novel immuno-oncology therapeutics for the treatment of cancer, today.
NEW YORK, Oct. 10, 2023 (GLOBE NEWSWIRE) Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related
NEW YORK, Sept. 26, 2023 Ovid Therapeutics Inc. , a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders,.
NEW YORK, Sept. 20, 2023 Ovid Therapeutics Inc. , a biopharmaceutical company committed to developing medicines that transform the lives of people with epilepsies and seizure-related disorders,.